ProLynx, founded in 2009 by Daniel V. Santi, M.D., Ph.D., and Gary W. Ashley, Ph.D., is a San Francisco-based company specializing in the controlled release of therapeutics. The company has developed advanced linker technologies that enable the sustained and predictable release of drugs, including peptides, proteins, and small molecules, from circulating and fixed macromolecular conjugates. ProLynx aims to overcome the limitations of current drug conjugates used for half-life extension, targeting the pharmaceutical and biotechnology markets.
Notable figures associated with ProLynx include its founders, Daniel V. Santi and Gary W. Ashley, who bring extensive expertise in medical and pharmaceutical sciences. The company has achieved significant milestones in drug delivery technology, particularly with its β-eliminative drug delivery system. This innovative approach has positioned ProLynx as a leader in the field of therapeutic release, making a substantial impact on the efficacy and predictability of drug therapies.
